Selective NLRP3 Inhibitor Compounds for Improved Drug Properties
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for NLRP3 inflammasome-related disorders lack compounds with improved physicochemical, pharmacological, and pharmaceutical properties, and existing inhibitors are either non-specific or have undesirable side effects.
Innovation Solution
Development of novel compounds, including specific inhibitors of the NLRP3 inflammasome, which are designed to modulate NLRP3-dependent cellular processes with enhanced properties for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NLRP3 inhibitors are used, then inflammasome activity is suppressed, but the compounds lack improved physicochemical, pharmacological and pharmaceutical properties
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of NLRP3 inhibitors, including introducing specific functional groups (carboxylic acid, hydroxyl, amino), adjusting molecular weight ranges (200-500 Da), optimizing logP values (0.5-3.0), and controlling pKa values. These parameter optimizations transform existing inhibitors into compounds with improved physicochemical properties while maintaining inflammasome inhibition efficacy.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine multiple functional moieties within single inhibitor compounds. Examples include molecules integrating both carboxylic acid and hydroxyl groups, or combining aromatic rings with aliphatic chains, achieving synergistic effects that improve both efficacy and pharmacological properties simultaneously.
2Reliability
If existing NLRP3 inhibitors are used, then inflammasome activity is suppressed, but side effects are undesirable
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions within the molecular structure to achieve selective NLRP3 inhibition. Carboxylic acid groups at certain positions enhance binding affinity to NLRP3, while hydroxyl groups at other positions improve solubility and reduce off-target effects. This localized functional group placement enables selective inhibition with reduced side effects.
Solution Approach 2:
The patent uses copying by identifying and replicating successful structural motifs from known effective inhibitors while modifying other aspects to improve safety profile. Successful pharmacophores are copied and adapted with optimized substituents that maintain binding efficacy but reduce toxicity, creating next-generation inhibitors with improved safety characteristics.
3Reliability
If novel compounds are developed with improved properties, then therapeutic benefits are enhanced, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into manageable modules: identifying core pharmacophore structures, adding functional groups systematically, optimizing physical parameters, and validating through controlled assays. This modular approach reduces overall development complexity by breaking down the intricate task of creating novel inhibitors into discrete, manageable steps.
Solution Approach 2:
The patent employs universality by designing a comprehensive set of design rules and structural frameworks that can be applied across multiple inhibitor series. The same core principles of functional group selection, molecular weight optimization, and parameter tuning can be universally applied to generate inhibitors for different NLRP3-related indications, reducing the need to restart development for each new compound series.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I):and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.